On May 31, 2018 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO)
Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor
engineered T cell (CAR T) technology, reported that Manuel Litchman, M.D., President and Chief Executive
Officer, will present a company overview at two investor conferences in June (Press release, Mustang Bio, MAY 31, 2018, View Source [SID1234526979]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018, at 9 a.m. EDT at the Grand Hyatt in
New York City
JMP Securities Life Sciences Conference on Thursday, June 21, 2018, at 9:30 a.m. EDT at the St. Regis New York
in New York City
A live webcast of the Jefferies presentation will be available on the Events page of the Investor Relations section of
Mustang’s website: www.mustangbio.com. An archived replay of the webcast will be available for approximately 30
days following the presentation.